Table 2.
Impact of drug resistant mutations in the the hepatitis B virus Pol on the hepatitis B surface antigen
| Antiviral drugs | Resistance mutations | HBsAg corresponding changes |
| Lamivudine (LAM2) Tebivudine (LdT2) | rtL180M | No change |
| rtM204V | sI195M | |
| rtM204I2 | sW1961/S/L | |
| Adefovir (AdV) Tenofovir (TDF) LAM2 | rtA181T2 | sW1721 |
| rtA181T2 | sW172L | |
| rtA181V2 | sL173F | |
| rtN236T | After end of HBs open reading frame | |
| Entecavir (ETV) | rtI169T | sF161H/L |
| rtT184A | No change | |
| rtT184C | sL175F + sL176V | |
| rtT184I | No change | |
| rtT184G | sL176V | |
| rtT184S | sL175F | |
| rtT184M | sL1761 | |
| rt184L | sL175F | |
| rtS202C | No change/sS193F | |
| rtS202I | sV194F/S | |
| rtS202G | No change/sS193L | |
| rtM250I | After end of HBs open reading frame | |
| rtM250V | After end of HBs open reading frame |
1
Stop codon;
2
Cross-resistance. HBsAg: Hepatitis B surface antigen. Modified from Zoulim et al[38].